Publication
[177Lu]Lu-PSMA-617 Plus Short-Course Priming With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Single-Arm Phase 2 Trial (Lu-PRIME).
Piyush Aggarwal, Ashwani Sood, Swayamjeet Satapathy, Shikha Goyal, Komalpreet Kaur, Gaurav Prakash, Kannan Periasamy, Bhagwant Rai Mittal
- Source
- PubMed
- Retrieved
- Sep 14, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260914-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: [177Lu]Lu-PSMA-617 has been an approved treatment modality for metastatic castration-resistant prostate cancer (mCRPC). Recent studies have shown PSMA upregulation following enzalutamide, which may enhance the outcomes with [177Lu]Lu-PSMA-617. This study aims to evaluate the efficacy…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available